VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Oliver Gautschi; Anne-Marie Dingemans; Susanne Crowe; Solange Peters; Heinrich Roder; Julia Grigorieva; Joanna Roder; Francesco Zappa; Miklos Pless; Martin Brutsche; Florent Baty; Lukas Bubendorf; Shu-Fang Hsu Schmitz; Kyung-Jae Na; David Carbone; Rolf Stahel; Egbert Smit

doi:10.1016/j.lungcan.2012.10.006

VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Oliver Gautschi^*, Anne-Marie Dingemans, Susanne Crowe, Solange Peters, Heinrich Roder, Julia Grigorieva, Joanna Roder, Francesco Zappa, Miklos Pless, Martin Brutsche, Florent Baty, Lukas Bubendorf, Shu-Fang Hsu Schmitz, Kyung-Jae Na, David Carbone, Rolf Stahel, Egbert Smit

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: VeriStrat (R) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p = 0.0027, HR = 0.480, 95% confidence interval: 0.294-0.784). Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

Original language	English
Pages (from-to)	59-64
Journal	Lung Cancer
Volume	79
Issue number	1
DOIs	https://doi.org/10.1016/j.lungcan.2012.10.006
Publication status	Published - Jan 2013

Keywords

Biomarker
Chemotherapy
EGFR inhibitor
Lung cancer
Personalized medicine
Proteomics

Access to Document

10.1016/j.lungcan.2012.10.006

Cite this

Gautschi, O., Dingemans, A.-M., Crowe, S., Peters, S., Roder, H., Grigorieva, J., Roder, J., Zappa, F., Pless, M., Brutsche, M., Baty, F., Bubendorf, L., Schmitz, S.-F. H., Na, K.-J., Carbone, D., Stahel, R., & Smit, E. (2013). VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. Lung Cancer, 79(1), 59-64. https://doi.org/10.1016/j.lungcan.2012.10.006

@article{827a14598ce9441d8d3250a03087a761,

title = "VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528",

abstract = "Background: VeriStrat (R) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p = 0.0027, HR = 0.480, 95% confidence interval: 0.294-0.784). Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients. ",

keywords = "Biomarker, Chemotherapy, EGFR inhibitor, Lung cancer, Personalized medicine, Proteomics",

author = "Oliver Gautschi and Anne-Marie Dingemans and Susanne Crowe and Solange Peters and Heinrich Roder and Julia Grigorieva and Joanna Roder and Francesco Zappa and Miklos Pless and Martin Brutsche and Florent Baty and Lukas Bubendorf and Schmitz, {Shu-Fang Hsu} and Kyung-Jae Na and David Carbone and Rolf Stahel and Egbert Smit",

year = "2013",

month = jan,

doi = "10.1016/j.lungcan.2012.10.006",

language = "English",

volume = "79",

pages = "59--64",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

Gautschi, O, Dingemans, A-M, Crowe, S, Peters, S, Roder, H, Grigorieva, J, Roder, J, Zappa, F, Pless, M, Brutsche, M, Baty, F, Bubendorf, L, Schmitz, S-FH, Na, K-J, Carbone, D, Stahel, R & Smit, E 2013, 'VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528', Lung Cancer, vol. 79, no. 1, pp. 59-64. https://doi.org/10.1016/j.lungcan.2012.10.006

VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. / Gautschi, Oliver; Dingemans, Anne-Marie; Crowe, Susanne et al.
In: Lung Cancer, Vol. 79, No. 1, 01.2013, p. 59-64.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

AU - Gautschi, Oliver

AU - Dingemans, Anne-Marie

AU - Crowe, Susanne

AU - Peters, Solange

AU - Roder, Heinrich

AU - Grigorieva, Julia

AU - Roder, Joanna

AU - Zappa, Francesco

AU - Pless, Miklos

AU - Brutsche, Martin

AU - Baty, Florent

AU - Bubendorf, Lukas

AU - Schmitz, Shu-Fang Hsu

AU - Na, Kyung-Jae

AU - Carbone, David

AU - Stahel, Rolf

AU - Smit, Egbert

PY - 2013/1

Y1 - 2013/1

N2 - Background: VeriStrat (R) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p = 0.0027, HR = 0.480, 95% confidence interval: 0.294-0.784). Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

AB - Background: VeriStrat (R) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p = 0.0027, HR = 0.480, 95% confidence interval: 0.294-0.784). Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

KW - Biomarker

KW - Chemotherapy

KW - EGFR inhibitor

KW - Lung cancer

KW - Personalized medicine

KW - Proteomics

U2 - 10.1016/j.lungcan.2012.10.006

DO - 10.1016/j.lungcan.2012.10.006

M3 - Article

C2 - 23122759

SN - 0169-5002

VL - 79

SP - 59

EP - 64

JO - Lung Cancer

JF - Lung Cancer

IS - 1

ER -